<DOC>
	<DOCNO>NCT00759200</DOCNO>
	<brief_summary>This study evaluate safety efficacy alb-interferon adult genotype 2 3 chronic hepatitis</brief_summary>
	<brief_title>Safety Efficacy Albumin Interferon Administered Every 4 Weeks Genotype 2/3 Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age 18 year old Clinical diagnosis chronic hepatitis C Infection HCV genotype 2 3 No previous IFNÎ±based therapy Women childbearing potential use double barrier method contraception , pregnant nursing Fertile male , unless condom spermicide use female partner agree use one acceptable method 7 month last dose RBV History current evidence decompensated liver disease ; form liver disease Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) History moderate , severe uncontrolled psychiatric disease History seizure disorder History clinical evidence chronic cardiac disease , preexist interstitial lung disease severe lung disease Clinically significant finding eye/retinal examination History immunologically mediate disease Organ transplantation cornea hair transplant History clinically significant hemoglobinopathy Diagnosis malignancy organ system exception localize basal cell carcinoma skin History galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption History hypersensitivity study drug drug similar chemical structure Drug alcohol addiction within last 6 month and/or positive drug screening test Received systemic corticosteroid ( prednisone equivalent &gt; 10 mg/day ) within 14 day prior Baseline visit Received concomitant systemic antibiotic , antifungal antiviral treatment active infection within 14 day prior Baseline visit . Received herbal therapy ( include milk thistle glycyrrhizin ) investigational drug within 35 day prior Baseline visit Have clinically significant laboratory abnormality Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>genotype 2</keyword>
	<keyword>genotype 3</keyword>
	<keyword>albumin interferon alfa-2b</keyword>
	<keyword>alb-interferon</keyword>
</DOC>